{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:00:30Z","timestamp":1778504430551,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82173900"],"award-info":[{"award-number":["82173900"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Clinical Research Plan of SHDC","award":["SHDC2020CR4072"],"award-info":[{"award-number":["SHDC2020CR4072"]}]},{"name":"the 2022 Shanghai Young Pharmaceutical Talent Ability Enhancement Project","award":["HYHZ (2023) No. 04"],"award-info":[{"award-number":["HYHZ (2023) No. 04"]}]},{"name":"the Safety Evaluation of Carfilzomib in Special Populations Based on Mechanism-Based Models 2023 RADIANT CHINA-Pharmaceutical Research Capacity Building Fund Project"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"DOI":"10.1186\/s12920-025-02231-3","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:36:49Z","timestamp":1759847809000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Association of CYP3A5 rs15524 and CYP3A7 rs776744 polymorphisms on tac IPV and clinical outcomes in early post-heart transplantation"],"prefix":"10.1186","volume":"18","author":[{"given":"Yuhui","family":"Chai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lili","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiping","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danni","family":"Quan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuebin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"issue":"48","key":"2231_CR1","first-page":"1271","volume":"41","author":"CN Barnard","year":"1967","unstructured":"Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur hospital, cape town. S Afr Med J. 1967;41(48):1271\u20134.","journal-title":"S Afr Med J"},{"issue":"3","key":"2231_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261\u2013307.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"2231_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1432-2277.2011.01365.x","volume":"25","author":"A Capron","year":"2012","unstructured":"Capron A, Lerut J, Latinne D, Rahier J, Haufroid V, Wallemacq P. Correlation of tac levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. Transpl Int. 2012;25(1):41\u20137.","journal-title":"Transpl Int"},{"issue":"8","key":"2231_CR4","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.2215\/CJN.16421221","volume":"17","author":"KH Piburn","year":"2022","unstructured":"Piburn KH, Sigurjonsdottir VK, Indridason OS, Maestretti L, Patton MV, McGrath A, et al. Patterns in tac variability and association with De Novo Donor-Specific antibody formation in pediatric kidney transplant recipients. Clin J Am Soc Nephrol. 2022;17(8):1194\u2013203.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"2231_CR5","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1111\/ajt.15016","volume":"18","author":"I Gueta","year":"2018","unstructured":"Gueta I, Markovits N, Yarden-Bilavsky H, Raichlin E, Freimark D, Lavee J, et al. High tac trough level variability is associated with rejections after heart transplant. Am J Transpl. 2018;18(10):2571\u20138.","journal-title":"Am J Transpl"},{"issue":"2","key":"2231_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40620-015-0230-0","volume":"29","author":"JA O\u2019Regan","year":"2016","unstructured":"O\u2019Regan JA, Canney M, Connaughton DM, O\u2019Kelly P, Williams Y, Collier G, et al. Tac trough-level variability predicts long-term allograft survival following kidney transplantation. J Nephrol. 2016;29(2):269\u201376.","journal-title":"J Nephrol"},{"issue":"2","key":"2231_CR7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/TP.0000000000001129","volume":"101","author":"HR Whalen","year":"2017","unstructured":"Whalen HR, Glen JA, Harkins V, Stevens KK, Jardine AG, Geddes CC, et al. High intrapatient tac variability is associated with worse outcomes in renal transplantation using a Low-Dose tac immunosuppressive regime. Transplantation. 2017;101(2):430\u20136.","journal-title":"Transplantation"},{"issue":"4","key":"2231_CR8","doi-asserted-by":"publisher","first-page":"100878","DOI":"10.1016\/j.trre.2024.100878","volume":"38","author":"H Chen","year":"2024","unstructured":"Chen H, Liu S, Yu L, Hou X, Zhao R. Factors and interventions affecting tac IPV: A systematic review and meta-analysis. Transpl Rev (Orlando). 2024;38(4):100878. https:\/\/doi.org\/10.1016\/j.trre.2024.100878.","journal-title":"Transpl Rev (Orlando)"},{"issue":"1","key":"2231_CR9","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/FTD.0b013e3181c49a4c","volume":"32","author":"J Yong Chung","year":"2010","unstructured":"Yong Chung J, Jung Lee Y, Bok Jang S, Ahyoung Lim L, Soo Park M, Hwan Kim K. CYP3A5*3 genotype associated with intrasubject Pharmacokinetic variation toward tac in bioequivalence study. Ther Drug Monit. 2010;32(1):67\u201372.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"2231_CR10","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.transproceed.2019.04.019","volume":"51","author":"CY Cheung","year":"2019","unstructured":"Cheung CY, Chan KM, Wong YT, Chak WL, Bekers O, van Hooff JP. Impact of CYP3A5 genetic polymorphism on IPV of tac exposure in Chinese kidney transplant recipients. Transpl Proc. 2019;51(6):1754\u20137.","journal-title":"Transpl Proc"},{"issue":"5","key":"2231_CR11","doi-asserted-by":"publisher","first-page":"823","DOI":"10.3390\/jpm12050823","volume":"12","author":"K Sridharan","year":"2022","unstructured":"Sridharan K, Shah S, Jassim A, Hammad M, Ebrahim Al Gadhban J, Al Segai O. Evaluation of pharmacogenetics of drug-metabolizing enzymes and drug efflux transporter in renal transplants receiving immunosuppressants. J Pers Med. 2022;12(5):823\u201337.","journal-title":"J Pers Med"},{"issue":"18","key":"2231_CR12","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.2217\/pgs.15.138","volume":"16","author":"K Aouam","year":"2015","unstructured":"Aouam K, Kolsi A, Kerkeni E, Ben Fredj N, Chaabane A, Monastiri K, et al. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tac exposure in kidney transplant recipients: a study according to the post-transplant phase. Pharmacogenomics. 2015;16(18):2045\u201354.","journal-title":"Pharmacogenomics"},{"issue":"9","key":"2231_CR13","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1111\/ajt.13309","volume":"15","author":"MA Sikma","year":"2015","unstructured":"Sikma MA, van Maarseveen EM, van de Graaf EA, et al. Pharmacokinetics and toxicity of tac early after heart and lung transplantation. Am J Transpl. 2015;15(9):2301\u201313.","journal-title":"Am J Transpl"},{"issue":"5","key":"2231_CR14","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.healun.2022.10.015","volume":"42","author":"A Velleca","year":"2023","unstructured":"Velleca A, Shullo MA, Dhital K, Azeka E, Colvin M, DePasquale E, et al. The international society for heart and lung transplantation (ISHLT) guidelines for the care of heart transplant recipients. J Heart Lung Transpl. 2023;42(5):e1\u2013141.","journal-title":"J Heart Lung Transpl"},{"issue":"04","key":"2231_CR15","first-page":"301","volume":"10","author":"WQ Chen","year":"2022","unstructured":"Chen WQ, Zhang L, zhang Y, et al. Expert consensus on individualized treatment of tac in solid organ transplantation. Prac J Organ Transpl. 2022;10(04):301\u20138.","journal-title":"Prac J Organ Transpl"},{"issue":"5","key":"2231_CR16","doi-asserted-by":"publisher","first-page":"e13494","DOI":"10.1111\/petr.13494","volume":"23","author":"MV Yanik","year":"2019","unstructured":"Yanik MV, Seifert ME, Locke JE, Hauptfeld-Dolejsek V, Crowley MR, Cutter GR, et al. CYP3A5 genotype affects time to therapeutic tac level in pediatric kidney transplant recipients. Pediatr Transpl. 2019;23(5):e13494.","journal-title":"Pediatr Transpl"},{"issue":"6","key":"2231_CR17","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s13318-018-0478-6","volume":"43","author":"T Uno","year":"2018","unstructured":"Uno T, Wada K, Matsuda S, Terada Y, Oita A, Kawase A, et al. Impact of the CYP3A5*1 allele on the pharmacokinetics of tac in Japanese heart transplant patients. Eur J Drug Metab Pharmacokinet. 2018;43(6):665\u201373.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"2231_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1515\/dmpt-2016-0036","volume":"32","author":"EY Tamashiro","year":"2017","unstructured":"Tamashiro EY, Felipe CR, Genvigir FDV, Rodrigues AC, Campos AB, Hirata RDC, et al. Influence of CYP3A4 and CYP3A5 polymorphisms on tac and sirolimus exposure in stable kidney transplant recipients. Drug Metab Pers Ther. 2017;32(2):89\u201395.","journal-title":"Drug Metab Pers Ther"},{"issue":"14","key":"2231_CR19","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/pgs-2021-0083","volume":"22","author":"J Liu","year":"2021","unstructured":"Liu J, Feng D, Kan X, Zheng M, Zhang X, Wang Z, et al. Polymorphisms in the CYP3A5 gene significantly affect the pharmacokinetics of sirolimus after kidney transplantation. Pharmacogenomics. 2021;22(14):903\u201312.","journal-title":"Pharmacogenomics"},{"key":"2231_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2012.00248","volume":"3","author":"R Wei","year":"2012","unstructured":"Wei R, Yang F, Urban TJ, Li L, Chalasani N, Flockhart DA, et al. Impact of the interaction between 3\u2019-UTR SNPs and microRNA on the expression of human xenobiotic metabolism enzyme and transporter genes. Front Genet. 2012;3:248.","journal-title":"Front Genet"},{"issue":"27","key":"2231_CR21","doi-asserted-by":"publisher","first-page":"24280","DOI":"10.1074\/jbc.M202345200","volume":"277","author":"O Burk","year":"2002","unstructured":"Burk O, Tegude H, Koch I, Hustert E, Wolbold R, Glaeser H, et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem. 2002;277(27):24280\u20138.","journal-title":"J Biol Chem"},{"issue":"16","key":"2231_CR22","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.2217\/pgs-2017-0127","volume":"18","author":"B Sun","year":"2017","unstructured":"Sun B, Guo Y, Gao J, Shi W, Fan G, Li X, et al. Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients. Pharmacogenomics. 2017;18(16):1503\u201313.","journal-title":"Pharmacogenomics"},{"issue":"1","key":"2231_CR23","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1038\/s41598-020-58225-x","volume":"10","author":"M Sohn","year":"2020","unstructured":"Sohn M, Kim MG, Han N, Kim IW, Gim J, Min SI, et al. Author correction: whole exome sequencing for the identification of CYP3A7 variants associated with tac concentrations in kidney transplant patients. Sci Rep. 2020;10(1):2486.","journal-title":"Sci Rep"},{"issue":"11","key":"2231_CR24","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1111\/cts.13398","volume":"15","author":"JM Collins","year":"2022","unstructured":"Collins JM, Nworu AC, Mohammad SJ, Li L, Li C, Li C, et al. Regulatory variants in a novel distal enhancer regulate the expression of CYP3A4 and CYP3A5. Clin Transl Sci. 2022;15(11):2720\u201331.","journal-title":"Clin Transl Sci"},{"issue":"2","key":"2231_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","volume":"29","author":"N Shuker","year":"2015","unstructured":"Shuker N, van Gelder T, Hesselink DA. Intra-patient variability in tac exposure: causes, consequences for clinical management. Transpl Rev (Orlando). 2015;29(2):78\u201384.","journal-title":"Transpl Rev (Orlando)"},{"issue":"1","key":"2231_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/FTD.0b013e3181c49a4c","volume":"32","author":"J Yong Chung","year":"2010","unstructured":"Yong Chung J, Jung Lee Y, Bok Jang S, Ahyoung Lim L, Soo Park M, Hwan Kim K. CYP3A5*3 genotype associated with intrasubject Pharmacokinetic variation toward tacrolimus in bioequivalence study. Ther Drug Monit. 2010;32(1):67\u201372.","journal-title":"Ther Drug Monit"},{"issue":"6","key":"2231_CR27","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.transproceed.2019.04.019","volume":"51","author":"CY Cheung","year":"2019","unstructured":"Cheung CY, Chan KM, Wong YT, Chak WL, Bekers O, van Hooff JP. Impact of CYP3A5 genetic polymorphism on intrapatient variability of tacrolimus exposure in Chinese kidney transplant recipients. Transplant Proc. 2019;51(6):1754\u20137.","journal-title":"Transplant Proc"},{"issue":"21","key":"2231_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11216320","volume":"11","author":"A Nuchjumroon","year":"2022","unstructured":"Nuchjumroon A, Vadcharavivad S, Singhan W, Poosoonthornsri M, Chancharoenthana W, Udomkarnjananun S, et al. Comparison of tacrolimus intra-patient variability during 6\u201312 months after kidney transplantation between CYP3A5 expressers and nonexpressers. J Clin Med. 2022;11(21):6320.","journal-title":"J Clin Med"},{"issue":"1","key":"2231_CR29","doi-asserted-by":"publisher","first-page":"21389","DOI":"10.1038\/s41598-021-00942-y","volume":"11","author":"M D\u00e9ri","year":"2021","unstructured":"D\u00e9ri M, Szak\u00e1l-T\u00f3th Z, Fekete F, Mang\u00f3 K, Incze E, Minus A, et al. CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients. Sci Rep. 2021;11(1):21389.","journal-title":"Sci Rep"},{"issue":"9","key":"2231_CR30","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.1093\/ndt\/gfr253","volume":"26","author":"F Glowacki","year":"2011","unstructured":"Glowacki F, Lionet A, Buob D, Labalette M, Allorge D, Prov\u00f4t F, et al. CYP3A5 and ABCB1 polymorphisms in donor and recipient: impact on tac dose requirements and clinical outcome after renal transplantation. Nephrol Dial Transpl. 2011;26(9):3046\u201350.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"2231_CR31","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/j.1432-2277.2012.01446.x","volume":"25","author":"G Gervasini","year":"2012","unstructured":"Gervasini G, Garcia M, Macias RM. Impact of genetic polymorphisms on tac pharmacokinetics and the clinical outcome of renal transplantation. Transpl Int. 2012;25(4):471\u201380.","journal-title":"Transpl Int"},{"issue":"11","key":"2231_CR32","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/FPC.0b013e32834a48ca","volume":"21","author":"HL Tang","year":"2011","unstructured":"Tang HL, Xie HG, Yao Y, Hu YF. Lower tac daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers. Pharmacogenet Genomics. 2011;21(11):713\u201320.","journal-title":"Pharmacogenet Genomics"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02231-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-025-02231-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-025-02231-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T14:36:50Z","timestamp":1759847810000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-025-02231-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2231"],"URL":"https:\/\/doi.org\/10.1186\/s12920-025-02231-3","relation":{},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,7]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Shanghai Changhai Hospital (CHEC 2021\u2009\u2212\u2009133). Due to our study is a retrospective study, which only collects patients\u2019 clinical data (including demographic characteristics, diagnosis, curative effect evaluation, drug use, etc.) does not interfere with patients\u2019 treatment, examination and follow-up, does not collect patients\u2019 specimens, does not affect patients\u2019 medical rights and interests, and does not increase patients\u2019 risks, medical ethics committee of Shanghai Changhai Hospital waived the need of obtaining informed consent. All subjects studied were of Chinese and no prisoners were included. This study performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All the organs used in this study are from non-prisoner individuals who donate voluntarily, and the donation process conforms to national laws, regulations and ethical standards. All donors or their families have signed a written informed consent form to clearly know the purpose of the organ and the purpose of the study. The organs\/tissues used in this study were formally obtained from the Organ Transplantation Center of the First Affiliated Hospital of Navy Medical University.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"151"}}